NMPA Party Committee Secretary and Director Li Li Presided Over a Meeting to Advance Comprehensive Deepening of Pharmaceutical Regulatory Reform

On February 26, Li Li, Secretary of the Party Leadership Group and Director of the National Medical Products Administration, conducted research and presided over a meeting at the Beijing Yizhuang office area of the directly affiliated units of the National Medical Products Administration. The meeting focused on further deepening the reform of drug regulation. Li Li emphasized the need to further strengthen confidence in reform, maintain determination and resilience, and deepen regulatory reforms to strengthen the foundation, address shortcomings, and solve problems. This will help ensure high-level safety, promote high-quality development, and enhance vitality for a better quality of life.

He called for careful planning and improvement of the reform measures for the drug safety responsibility system, further improving mechanisms to support high-quality development of the pharmaceutical industry, actively promoting the coordinated development and governance of the “Three Medicals” (medical treatment, medical insurance, and medicine procurement), and advancing the integration of good laws, good governance, and regulatory reform.

Li Li stressed the importance of high-quality party building to promote the implementation of reforms, strengthening the Party’s leadership and Party building efforts, and solidly carrying out education on establishing and practicing correct views on political achievements.

He also highlighted the need to enhance regulatory capabilities to ensure reform implementation, scientifically formulate the “14th Five-Year Plan,” strengthen technical support capacity, accelerate the development of regulatory informatization, and advance scientific drug regulation.

Finally, Li Li called for a spirited attitude to promote reform, emphasizing systemic thinking, gathering strength from all parties, and increasing the overall, precise, and effective efforts to overcome challenges. This will accelerate China’s transition from a major pharmaceutical manufacturing country to a powerful pharmaceutical nation, better safeguarding the safety, effectiveness, and accessibility of medicines for the people.